Conference Day One
7:30 Check-In & Coffee
8:30 Chair’s Opening Remarks
8:40 Panel Discussion: Reflecting on Lessons Learned from PhII/III Failures to Drive Urgency for Novel CNS Biomarker Research
Synopsis
- Evaluating past failures to identify key missteps, avoid repeating errors, and foster collective learning that propels the field forward with greater cohesion
- The blood-based biomarker revolution: Reviewing the latest progress to increase accessibility, sensitivity and scalability
- Evaluating the latest progress in neuroimaging technologies: Enhancing clinical value, navigating constraints, and integrating with fluid-based approaches
9:30 Driving Precision Medicine in Neurology Through Biomarker-Driven Development
Synopsis
- Exploring biomarker strategies across neurodegenerative therapeutic programs, including Alzheimer’s and rare diseases
- Insights into the application of targeted antibody therapies in advancing clinical development strategies
10:00 Morning Break & Speed Networking
Synopsis
As this community unites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.
Tackling Sample Acquisition & Quality for Highly Precise & Improved Assay Validation
11:30 Optimizing Sample Quality for Improved Clinical Biomarker Reliability, Reproducibility & Data Integrity
Synopsis
- Addressing poorly characterized commercial samples; lack of clinical metadata and Biobank limitations (low volume, poor metadata, inconsistent storage)
- Ensuring the stability of proteins, nucleic acids, and other key analytes during storage and handling in clinical workflows
- Addressing the antibody issue: variability in commercial reagents with unverified clones and poor specificity impacting clinical assay performance
12:00 Panel Discussion: Exploring Sensitivity, Specificity, Credibility & Efficiency of Different Biomarker Detection Platforms for Technological Calibration
Synopsis
- Assessing the sensitivity levels of different techniques for biomarker measurement, such as aptamer-based proteomics assays, liquid chromatography–mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
- Exploring how individual biomarkers are suited to different measurement approaches
12:45 Lunch Break & Networking
Mapping Out the Future of Biomarkers: Emerging Trends & Strategies for Next-Gen Neuroscience Research
2:00 NExT – Neuro Expert Toolbox
Synopsis
- Introduction to Fujirebio Neuro Centre of Excellence – a collaborative environment which welcomes input from experts and partners around the world
- Learn about NExT – toolbox enables partners and customers to access Fujirebio’s expertise at every stage of biomarker development
- From pioneering work in Alzheimer’s diagnostics to a broader vision across the full spectrum of neurological conditions
2:30 Roundtable Discussion: Breakthrough Biomarkers on the Horizon to Stay Ahead of the Curve in Diagnostics & Therapeutics
Synopsis
Join leaders from across academia, industry, and tech to explore the most promising novel and emerging biomarkers transforming neuroscience research:
- Circular RNA: Potential roles in neurodegenerative disease pathogenesis and detection
- Cryptic protein markers: Uncovering hidden drivers of disease and therapeutic response
- Exosome-derived biomarkers: Tapping into extracellular vesicles for CNS signal access
- Immune cell biomarkers: Peripheral immune signatures reflecting neuroinflammatory processes
- Intracellular biomarkers: Tracking cellular-level changes linked to disease progression
- Preventative vaccines approach for neurodegenerative approaches
3:00 Session Reserved for Alamar Biosciences
3:30 Afternoon Break & Poster Session
Synopsis
This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.
4:00 Scrutinizing TDP-43 to Revitalize Hope & Restore Research Momentum
Synopsis
- How far away are we from having established blood-based biomarkers for TDP-43?
- How can we use p-Tau 217 as a gold standard for TDP-43?
- How can we differentiate Alzheimer’s, ALS, and Dementia?
- Deciphering TDP-43 Protein aggregates using seed amplification assays and single-particle proteomics
Unified Effort: Collaboration From Academia to Industry & Everything in Between to Identify a Common Goal & Accelerate Biomarker Innovation
4:30 Bridging the Disconnection Between Academia & Clinical Reality to Bridge Translational Gaps & Create a United Language
Synopsis
- How to optimize researchers’ data for seamless clinical translation
- Aligning priorities: Discovery science vs commercial deliverables
5:00 CNS Biomarker Innovation: What Does it Mean for the Patient?
Synopsis
- Highlighting the importance of advanced diagnostic tools for patient enrolment
- Reviewing clinical experience to optimize clinical recruitment and retention
- From invasive diagnostic procedures to novel omics technologies highlighting what’s truly most important for the patient